Statement from CEPI CEO, Dr Richard Hatchett, welcoming the Emergency Use Listing (EUL) for NVX-CoV2373:
"At this worrying stage of the pandemic, it is hugely welcome news that the world now has a powerful new weapon in its arsenal of tools to fight COVID-19.
"Novavax's vaccine is the first protein-based COVID-19 vaccine to receive Emergency Use Listing — a prerequisite for distribution by COVAX - which means it is now poised to play a central role in COVAX's mission to protect those most at risk from the virus.
"NVX-CoV2373 is safe, effective against multiple variants, and can be stored in a regular refrigerator so it can be rolled out easily without costly and burdensome cold chain requirements.
"With over 1 billion doses accessible to COVAX, I expect this CEPI-supported vaccine to make a significant contribution to controlling the pandemic globally."
About CEPI's investments in NVX-CoV2373
CEPI was one of the first investors in Novavax's COVID-19 vaccine candidate, NVX-CoV2373, and has to date provided up to US $399 million in funding to accelerate development and manufacturing of the vaccine for equitable global allocation.
In March 2020, CEPI provided up to US $4 million for Novavax to use their recombinant protein nanoparticle technology to develop a vaccine candidate against COVID-19.
CEPI's second investment, in May 2020, provided up to US $384 million to support preclinical studies, Phase 1 and Phase 2 clinical trials. The additional funding also supported the transfer of NVX-CoV2373 technology to manufacturing partners in different geographical regions for large-scale production of the vaccine. These investments were directly linked to equitable access commitments which have been key to enabling access to the vaccine through COVAX.
CEPI and Clover expand partnership for COVID-19 vaccine to include evaluation as a booster
University of Oxford's Prof. Dame Sarah Gilbert and CEPI's Dr. Richard Hatchett: "No one is safe, until we are all safe”
